Ciclopirox phosphoryloxymethyl ester - CicloMed

Drug Profile

Ciclopirox phosphoryloxymethyl ester - CicloMed

Alternative Names: Ciclopirox prodrug - CicloMed; CPX - CicloMed; CPX-POM

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Kansas
  • Developer CicloMed; University of Kansas
  • Class Antineoplastics
  • Mechanism of Action Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bladder cancer

Most Recent Events

  • 29 Nov 2017 CicloMed plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA in January 2018 (NCT03348514)
  • 26 Oct 2017 University of Kansas has a pending patent application for ciclopirox prodrug for the treatment of Bladder cancer in USA
  • 11 Oct 2017 Early research in Bladder cancer in USA (SC) )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top